BMC Surgery (May 2022)

Clinicopathological study of gastric schwannoma and review of related literature

  • Zhihan Zhong,
  • Yuhao Xu,
  • Junwei Liu,
  • Chengwu Zhang,
  • Zunqiang Xiao,
  • Yan Xia,
  • Yu Wang,
  • Jianfeng Wang,
  • Qiuran Xu,
  • Yi Lu

DOI
https://doi.org/10.1186/s12893-022-01613-z
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background This study aimed to investigate the clinical features, diagnostic criteria, treatment options, and prognosis of patients with gastric schwannoma (GS). Methods We collected the clinical data of all patients pathologically diagnosed with GS in Zhejiang Provincial People's Hospital from May 2012 to October 2021. Results A total of 26 cases of GS were analyzed clinicopathologically, where the sizes of the tumor were found to be in the range of 1–6 cm (mean: 3.16 cm, median: 3.05 cm). A computed tomography (CT) scan analysis revealed that most masses were either moderately progressive or uniformly enhanced. According to ultrasound gastroscopy results, most of them were hypoechoic masses. There were 23 cases of surgery and three cases of endoscopic submucosal tumor dissection. Immunohistochemistry demonstrated that S100 was positive in 26 patients, immunomarker SOX10 was positive in five, whereas CD34, CD117, and SMA were negative in most patients. CK (Pan), Dog-1, and Desmin were also found negative. All 26 cases were followed up after the conclusion of the study where no evidence of recurrence or metastasis was observed. Conclusions GS is a unique form of peripheral schwannoma. The diagnosis of this type of tumor depends on the pathology and immunohistochemistry of the individual. The key to treating this type of tumor is endoscopy and surgery. Follow up and related literature review showed that GS was a benign tumor with little possibility of malignant transformation.

Keywords